Evidence map›Paper›PMID 25437280›Full record

ReviewRheumatic diseases clinics of North America2014

Insights from populations at risk for the future development of classified rheumatoid arthritis.

V Michael Holers

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Rheumatic diseases clinics of North America, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Risk factors and disease mechanisms in myositis.Nature reviews. Rheumatology · 2018
    Review
  2. Biomarkers to guide clinical therapeutics in rheumatology?Current opinion in rheumatology · 2016
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

V Michael HolersDivision of Rheumatology, University of Colorado School of Medicine, Room 3102E, 1775 Aurora Court, Aurora, CO 80045, USA. Electronic address: Michael.Holers@ucdenver.edu.

Funding

Prevention Center U01: Early Targets for Antigen-Specific Tolerance Induction in Preclinical Rheumatoid ArthritisU01AI101981 · NIAID · UNIVERSITY OF COLORADO DENVER · PI HOLERS, VERNON MICHAEL · 2012 to 2021
$6.2M
Research Training in Rheumatology INCLUDE Down Syndrome SupplementT32AR007534 · NIAMS · UNIVERSITY OF COLORADO DENVER · PI Kristine A. Kuhn · 1986 to 2026
$6.1M
RA-Related Autoantibodies in Healthy FDR of RA PatientsR01AR051394 · NIAMS · UNIVERSITY OF COLORADO DENVER · PI NORRIS, JILL M · 2005 to 2011
$3.0M
Colorado Autoimmunity Center of ExcellenceUM1AI110503 · NIAID · UNIVERSITY OF COLORADO DENVER · PI HOLERS, VERNON MICHAEL · 2014 to 2018
$543k
NIAID NIH HHS U01 AI101981NIAID NIH HHS UM1 AI110503NIAMS NIH HHS R01 AR051394NIAMS NIH HHS T32 AR007534
6 · The paper itself

Abstract

Rheumatoid arthritis (RA) develops through a series of stages. In the seropositive subset of classified RA patients, a preclinical stage is present for years before the onset of clinically apparent disease. Relevant preclinical biomarkers include autoantibodies, alterations of lymphoid populations, elevated cytokines/chemokines, genetic/genomic factors, imaging studies, clinical findings, dietary and environmental biomarkers, cardiovascular disease risk assessment, microbiome analyses, and metabolomic changes. Identifying the population of asymptomatic subjects at sufficiently high risk for disease to be informative and representative of "preclinical patients" is a challenge. This article reviews the results of analyses that have been undertaken in these "at-risk" subjects.

Indexed as

Asymptomatic DiseasesArthritis, RheumatoidAutoantibodiesDisease ProgressionEpitopesHumansPeptides, CyclicRheumatoid FactorRiskAutoantibodiescyclic citrullinated peptideEpitopesPeptides, CyclicRheumatoid FactorAutoantibodiesBiomarkersDietary factorsEpidemiologyImagingPreclinical rheumatoid arthritisPredictionPrevention

Identifiers

PMID25437280
PMCPMC4250577

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.